Cervical Cancer Screening

2008 ◽  
Vol 6 (1) ◽  
pp. 58 ◽  
Author(s):  
_ _
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Current Method ◽  
Dna Testing ◽  
Abnormal Cytology ◽  
Hpv Dna ◽  
Hpv Dna Testing ◽  
Recent Version

Cervical carcinoma remains a health issue for women worldwide. Cervical cytology screening is the current method for early detection, and the NCCN Cervical Cancer Screening Clinical Practice Guidelines in Oncology provide direction for evaluating and managing this process, including clarified and revised recommendations on screening techniques and intervals and follow-up of abnormal screening results, including colposcopy. Human papillomavirus (HPV) DNA testing for primary cervical cancer has been approved by the FDA, and HPV DNA testing for high-risk virus types can also be used as a component of both primary screening and workup of abnormal cytology results. Colposcopy, along with colposcopically directed biopsies, has become the primary method for evaluating women with abnormal cervical cytologies. Special considerations for colposcopy performed during pregnancy are also discussed. For the most recent version of the guidelines, please visit NCCN.org

scholarly journals P824 Accuracy of cervical cancer screening using a self-collected vial for HPV DNA testing among adult women in sub-saharan africa

2019 ◽  
Author(s):  
Zita Aleyo Nodjikouambaye ◽  
Damtheou Sadjoli ◽  
Ralph Sydney Mboumba Bouassa ◽  
Hélène Péré ◽  
David Veyer ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Sub Saharan Africa ◽  
Adult Women ◽  
Dna Testing ◽  
Hpv Dna ◽  
Hpv Dna Testing ◽  
Sub Saharan

Home-based urinary HPV DNA testing in women who do not attend cervical cancer screening clinics

2015 ◽  
Vol 71 (3) ◽  
pp. 377-384 ◽  
Author(s):  
Alexandra Ducancelle ◽  
Justine Reiser ◽  
Adeline Pivert ◽  
Hélène Le Guillou-Guillemette ◽  
Anne Sophie Le Duc-Banaszuk ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Dna Testing ◽  
Hpv Dna ◽  
Hpv Dna Testing ◽  
Home Based

scholarly journals HPV DNA Testing in Cervical Cancer Screening

JAMA ◽  
2000 ◽  
Vol 283 (1) ◽  
pp. 87 ◽  
Author(s):  
Mark Schiffman ◽  
Rolando Herrero ◽  
Allan Hildesheim ◽  
Mark E. Sherman ◽  
Maria Bratti ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Dna Testing ◽  
Hpv Dna ◽  
Hpv Dna Testing

Oncogenic HPV-DNA testing alone as cervical cancer screening in high-risk population of Southern Mexico

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 16519-16519
Author(s):  
F. Gutierrez-Delgado ◽  
J. E. Enriquez-Freire ◽  
H. Leon-Velasco ◽  
J. A. Manzur-Perez ◽  
A. Baron-Rojas ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Cervical Cancer Screening ◽  
High Risk Population ◽  
Dna Testing ◽  
Southern Mexico ◽  
Hpv Dna ◽  
Hpv Dna Testing ◽  
Oncogenic Hpv

Human Telomerase RNA Gene Amplification Detection Increases the Specificity of Cervical Intraepithelial Neoplasia Screening

2010 ◽  
Vol 20 (6) ◽  
pp. 912-917 ◽  
Author(s):  
Lei Zheng ◽  
Ai-Lan Liu ◽  
Tao Qi ◽  
Qian Wang ◽  
Zhen Cai ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Screening ◽  
Cervical Cancer Screening ◽  
Intraepithelial Neoplasia ◽  
Dna Testing ◽  
Hpv Dna ◽  
Hpv Dna Testing ◽  
Cin Iii ◽  
Histopathologic Evaluation ◽  
Human Telomerase

Objectives:The purpose of this study was to evaluate the clinical significance of genomic amplification of the human telomerase RNA gene (TERC) for cervical cancer screening and explore whether it can serve as a biomarker to improve the specificity of human papillomavirus (HPV) DNA testing for cervical cancer screening.Methods:One hundred twenty women, including 20 cases of normal (control), 14 cases of cervical intraepithelial neoplasia grade I (CIN I), 35 cases of CIN II, 36 cases of CIN III, and 15 cases of squamous cervical cancer diagnosed by histopathologic evaluation, were subjected to cytopathologic examination, TERC detection by fluorescence in situ hybridization (FISH), and HPV DNA testing by Hybrid Capture II.Results:TERC amplification was significantly associated with cytopathologic diagnosis (P < 0.001) and histopathologic evaluation (P < 0.001). The positive rate of TERC gain was significantly higher in patients with CIN III or squamous cervical cancer than in patients with CIN I or those in the control group (P < 0.001). The specificity and positive predictive value of FISH for detecting CIN II or more severe cervical lesions (≥CIN II) were obviously higher than those of HPV DNA testing (97.1% vs 52.9%, 98.7% vs 83.8%).Conclusions:TERC amplification analyzed by FISH may serve as an adjunctive test to HPV DNA testing for improving the specificity and positive predictive value of cervical cancer screening.

Sign in / Sign up

Export Citation Format

Share Document